XML 48 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Data (Tables)
 3 Months Ended
Mar. 29, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Reportable Segment

Three Months Ended

March 29,
2019
 
March 30,
2018
Net sales:
 
 
 
Specialty Brands
$
547.3

 
$
548.4

Specialty Generics and Amitiza
243.3

 
206.9

Net Sales
$
790.6

 
$
755.3

Operating income:
 
 
 
Specialty Brands
$
242.0

 
$
242.1

Specialty Generics and Amitiza
57.9

 
34.2

Segment operating income
299.9

 
276.3

Unallocated amounts:
 
 
 
Corporate and unallocated expenses (1)          
(45.8
)
 
(44.0
)
Intangible asset amortization
(222.8
)
 
(178.0
)
Restructuring and related charges, net
(4.2
)
 
(28.2
)
Separation costs (2)
(11.7
)
 
—

Operating income (3)
$
15.4

 
$
26.1



(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.
(2)
Represents costs incurred related to the separation of the Company's Specialty Generics and Amitiza segment, which are included in SG&A.
(3)
The amount of operating loss included in the Company's unaudited condensed statement of income for the three months ended March 30, 2018 related to the Sucampo Acquisition was $30.7 million. Included within these results were $9.1 million of amortization associated with intangibles recognized from this acquisition and $15.0 million of expense associated with fair value adjustments of acquired inventory.
Schedule of Net Sales from External Customers by Products Net sales by product family within the Company's reportable segments were as follows:
 
Three Months Ended
 
March 29,
2019
 
March 30,
2018
Acthar Gel
$
223.9

 
$
243.8

Inomax
151.1

 
139.8

Ofirmev
95.6

 
82.0

Therakos
61.8

 
57.4

BioVectra
12.4

 
10.5

Other
2.5

 
14.9

Specialty Brands
547.3

 
548.4

 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
17.4

 
13.9

Oxycodone (API) and oxycodone-containing tablets
16.5

 
16.6

Acetaminophen (API)
46.2

 
49.4

Amitiza (1)
53.0

 
23.0

Other controlled substances
94.2

 
89.0

Other
16.0

 
15.0

Specialty Generics and Amitiza
243.3

 
206.9

Net Sales
$
790.6

 
$
755.3


(1) Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.